SEATTLE, Feb. 6, 2013 – Swedish Neuroscience Institute has added a new and innovative therapy to its treatment arsenal for glioblastoma multiforme (GBM) – a very aggressive and difficult to control brain tumor.
Nearly everyone notices vision problems, especially as you get older. In the great majority of cases, this is simply due to changes in the focusing capacity of the lens, and the solution is wearing glasses. However, it isn’t safe to assume that this is always the case. It’s important to have your eyes examined by a trained professional to determine whether something more serious is affecting the eye or the vision nerve.
In the video below you’ll learn about something I commonly see in my practice – vision loss from a tumor of the pituitary gland that is putting pressure on the vision nerves. This type of vision loss typically reduces the peripheral vision to either side. This can be diagnosed by a test at the eye doctor called Visual Fields. As in this case, a relatively simple operation can reverse the vision problem before it becomes permanent. The key is early diagnosis. If you notice that your peripheral vision is affected, ask your eye doctor to check visual fields.
Before they learn to crawl or walk, about 10,000 babies every year in the United States will develop a condition that will change how they will do just that. Cerebral palsy (CP) is a neurological condition caused by a brain injury before birth, during delivery or before a child’s second birthday. An estimated 800,000 Americans live with CP.
The most common symptom in CP is spasticity, an increase in muscle tension that impairs proper movement. Abnormal postures or movements, weakness or loss of muscle control and rigidity are also part of the constellation of CP signs and symptoms. While physical therapy remains the cornerstone for treatment, new medications and therapies for CP are being developed to help improve and manage symptoms.
Currently, Swedish Neuroscience Institute is participating in a study to determine the safety and tolerability of one such medication. Dalfampridine (AMPYRA ®) is a medication currently used to help improve walking speed in multiple sclerosis (MS) patients. This phase I clinical trial aims to evaluate AMPYRA’s® safety, tolerability and its effect on sensorimotor function of adults with CP. The study will look at how single and multiple doses of the medication have on CP patients, including:
- Hand strength
- Manual dexterity
- Walking speed
There is no cure for cerebral palsy. Therapies for CP ...
Swedish Foundation Raises $100 Million to Help Meet Increasing Demand for Regional Health-Care Services
SEATTLE, Oct. 26, 2012 – Swedish Medical Center's seven-year fund-raising initiative, called The Campaign for Swedish, has raised $103 million, exceeding its initial $100 million fund-raising goal in approximately five-and-a-half years. The Campaign, launched to help improve patient care and treatment options throughout the Swedish system, is the largest fund-raising effort undertaken by the private, non-profit health system to date.
On September 12, 2012, the Food and Drug Administration (FDA) approved teriflunomide for the treatment of multiple sclerosis (MS). Teriflunomide (AUBAGIO) is a once-daily pill for the treatment of relapsing forms of MS. Led by Dr. Lily Jung Henson, the Swedish Neuroscience Institute was among several clinical sites that tested the drug. Results of the research showed that teriflunomide can lessen MS disease activity. Specifically, it behaves similarly to injectable therapies by slowing MS relapse frequency, the rate of disability and MRI activity.
The safety profile, however, is more challenging than ....
SEATTLE, Aug. 29, 2012 - The Issaquah Press posted an article on their web site today headlined 'Issaquah brothers become brain surgeons for a day' about two Issaquah brothers who were among those invited by the Swedish Neuroscience Institute to become brain surgeons for a day on Aug. 24.
SEATTLE, Aug. 27, 2012 – Since its opening in 2008, the Ben & Catherine Ivy Center for Advanced Brain Tumor Treatment (the Ivy Center) at Swedish Medical Center's Neuroscience Institute has led the expansion drive of major research projects and expanded treatment options for patients living with brain cancer in the Pacific Northwest and throughout the world. The Ivy Center was founded in 2008 to create a world-class treatment and research facility focused on delivering excellent patient care and advancing progress toward more effective treatments for brain cancer.